DNAJC5 and tuberculosis: Our m8Δ/AAV1-Pv(s25-CSP-VK210/247) vaccine had 100% protective efficacy against the VK210 strain, and it offers a significant advantage by demonstrating TB effects against the VK210, VK247, and Pv-like strains.